Draft:Newron Pharmaceuticals
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Significa liberdade (talk | contribs) 4 months ago. (Update) |
| Company type | Società per azioni |
|---|---|
| SIX: NWRN | |
| ISIN | IT0004147952 |
| Industry | Pharmaceutical research |
| Headquarters | , |
 |
Newron Pharmaceuticals is an Italian pharmacy research company founded in 1999 and based in Bresso, near Milan. Its shares are traded on the Swiss Stock Exchange.
Safinamide, a drug against Parkinson's disease, was approved by the EU and Switzerland in 2015, and in 2017, by the U.S. FDA. Other drugs in development are ralfinamide against neuropathic pain, and evenamide to treat schizophrenia.